Olympus Corp Ord (OCPNF) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Olympus Corp..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.944 Today marks an exciting milestone, sharing with you the new Olympus strategy, 00:00:05.944 -- 00:00:11.315 one that builds on our evolution as a pure play medtech company, but also defines 00:00:11.315 -- 00:00:14.863 the next chapter with clarity and conviction. 00:00:14.863 -- 00:00:19.932 Let us begin with the world around us. Populations are aging quickly. 00:00:19.932 -- 00:00:23.937 Already, more than 40% of people are over 60. 00:00:23.937 -- 00:00:29.025 As people live longer, chronic diseases become more common, among them 00:00:29.025 -- 00:00:32.730 gastrointestinal, urological, and lung cancer. 00:00:32.730 -- 00:00:37.397 These trends are driving steady demand for endoscopy-enabled care. 00:00:37.397 -- 00:00:42.724 In value terms, the market grows at about 5% a year across the application 00:00:42.724 -- 00:00:48.034 field served by Olympus. In developed markets, Japan, Europe, the United 00:00:48.034 -- 00:00:53.040 States, and China, roughly 155 million endoscopy procedures 00:00:53.040 -- 00:00:58.167 are performed each year. Yet these regions represent only about 00:00:58.167 -- 00:01:01.191 a quarter of the world's population. 00:01:01.191 -- 00:01:06.357 As access to care rises in other markets, the total number of procedures could 00:01:06.357 -- 00:01:11.918 be nearly four times higher, around 600 million annually. 00:01:11.918 -- 00:01:17.749 What holds that potential back today are the barriers along the care pathway. 00:01:17.749 -- 00:01:21.736 Lack of clinician training and infrastructure in certain markets. 00:01:21.736 -- 00:01:26.902 Clinicians spending too much time on administrative work and documentation. 00:01:26.906 -- 00:01:32.592 Healthcare systems are under pressure. The overall cost of care ke...